Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster
Company aims to launch one new product or indication every 1.5 years on average, bolstered by external innovation Phase III assets xevinapant and evobrutinib are expected to drive next wave of launche